Targeting CDC-like kinases 2 and 3 (CLK2 and CLK3) has emerged as an effective therapeutic strategy in cancer treatment, with several compounds currently in clinical development.

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Abbott Laboratories recently received FDA clearance for Tendyne, its transcatheter mitral valve replacement system. The news comes on the heels of Edwards Lifesciences Corp. securing a CE mark for its ...

Silexion Therapeutics Corp. has released preclinical data demonstrating the efficacy of its next-generation RNA interference ...

Bioage Labs Inc. has completed IND-enabling studies for BGE-102, a structurally novel, orally available small-molecule NLRP3 ...

The U.S. Department of Justice is reshuffling its enforcement focus for the coming three years per a May 12 memo attributed to Matthew Galeotti, director of the department’s criminal division.

For the second time in as many months, the lack of statistically significant overall survival data sent shares of Summit Therapeutics Inc. sliding, despite otherwise positive findings for PD-1/VEGF ...

Despite the advancement of AI and machine learning technologies and their incorporation into cancer treatment and drug development, a lack of trust and understanding of these new approaches is ...

Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related deaths worldwide due to lack of effective diagnosis at early stages and limited comprehension of its pathogenesis, thus ...

In yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting Claudin 18.2 from Evopoint Biosciences Co. Ltd. for up to $1.34 billion.

Rona Therapeutics Co. Ltd. has reported preclinical data for its RNA interference (RNAi) therapy RN-026 targeting lipoprotein(a) (Lp[a]).

CSPC Pharmaceutical Group Ltd. on May 30 disclosed that the company was engaged in ongoing negotiations with unnamed, independent third parties regarding three license deals and collaborations that ...